Expands on the previously granted patents
covering the use of REQORSA in combination with immune checkpoint
inhibitors
AUSTIN,
Texas, Aug. 13, 2024 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that the Singapore Patent Office has granted a
patent to Genprex that covers the use of the Company's lead drug
candidate, Reqorsa® Gene Therapy, in combination with
anti-PD-1 antibodies through 2037.
This patent expands on the previously granted patents in the
U.S., Japan, Mexico, Russia, Australia, Chile, China
and Korea to cover the use of REQORSA in combination with an immune
checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean
patent also claims the use of REQORSA in combination with PD-L1
antibodies. Genprex will be pursuing additional patent applications
with claims to combinations of REQORSA and PD-L1 antibodies in the
US, Brazil, Canada, China, Europe
and Israel. Should these
applications grant, they would be applicable to Genprex's
Acclaim-3 clinical trial.
PD-1 inhibitors and PD-L1 inhibitors are a type of targeted
immunotherapy and a part of a group of checkpoint inhibitor
anti-cancer drugs that block the activity of PD-1 and PDL1 immune
checkpoint proteins present on the surface of cells.
"This patent expands our intellectual property portfolio,
providing us with additional protection and exclusivity for our
drug combinations with REQORSA and furthering our patent protection
in the Asian markets where lung cancer is the most prevalent," said
Thomas Gallagher, Esq., Senior Vice
President of Intellectual Property and Licensing at Genprex.
According to GLOBOCAN, in 2022 Asia accounted for 63% of new
lung cancer cases worldwide, which is equal to more than 1.5
million new cases of lung cancer per year. In 2022, China alone had more than 1 million new cases
of lung cancer.
The Acclaim-3 study is a Phase 1/2 clinical trial that uses a
combination of REQORSA and Genentech's Tecentriq® as
maintenance therapy for patients with extensive stage small cell
lung cancer (ES-SCLC) who developed tumor progression after
receiving Tecentriq and chemotherapy as initial standard treatment.
The Acclaim-3 clinical trial has received U.S. Food and Drug
Administration (FDA) Fast Track Designation for this patient
population, and Acclaim-3 has received FDA Orphan Drug
Designation.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex's technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches.
Genprex's oncology program utilizes its systemic, non-viral
Oncoprex® Delivery System which encapsulates the
gene-expressing plasmids using lipid-based nanoparticles in a
lipoplex form. The resultant product is administered intravenously,
where it is taken up by tumor cells that then express tumor
suppressor proteins that were deficient in the tumor. The Company's
lead product candidate, Reqorsa® Gene Therapy
(quaratusugene ozeplasmid), is currently being evaluated in two
clinical trials as a treatment for NSCLC and SCLC. Each of
Genprex's lung cancer clinical programs has received a Fast Track
Designation from the FDA for the treatment of that patient
population, and Genprex's SCLC program has received an FDA Orphan
Drug Designation. Genprex's diabetes gene therapy approach is
comprised of a novel infusion process that uses an AAV vector to
deliver Pdx1 and MafA genes directly to the pancreas. In models of
Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas
into functional beta-like cells, which can produce insulin but may
be distinct enough from beta cells to evade the body's immune
system. In a similar approach, GPX-002 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are made on the basis of
the current beliefs, expectations and assumptions of management,
are not guarantees of performance and are subject to significant
risks and uncertainty. These forward-looking statements should,
therefore, be considered in light of various important factors,
including those set forth in Genprex's reports that it files from
time to time with the Securities and Exchange Commission and which
you should review, including those statements under "Item 1A – Risk
Factors" in Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines and specifications; the timing
and success of Genprex's clinical trials and regulatory approvals;
the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; the
effects of any strategic research and development prioritization
initiatives, and any other efforts that Genprex takes or may take
in the future that are aimed at optimizing and re-focusing
Genprex's oncology and/or other clinical development programs
including prioritization of resources, and the extent to which
Genprex is able to implement such efforts and initiatives
successfully to achieve the desired and intended results thereof;
Genprex's future growth and financial status, including Genprex's
ability to maintain compliance with the continued listing
requirements of The Nasdaq Capital Market and to continue as a
going concern and to obtain capital to meet its long-term liquidity
needs on acceptable terms, or at all; Genprex's commercial and
strategic partnerships, including those with its third party
vendors, suppliers and manufacturers and their ability to
successfully perform and scale up the manufacture of its product
candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor
Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-granted-patent-in-singapore-for-reqorsa-gene-therapy-with-pd-1-antibodies-to-treat-cancers-302220830.html
SOURCE Genprex, Inc.
